Dr Reddys Laboratories Ltd share price logo

Dr Reddys Laboratories Ltd (DRREDDY)

₹6820.150.65%

bell
Get free price alerts. Set up your Free investment account to get Live Prices.

🔔 Stock Split Alert

Dr Reddys Laboratories to consider proposal for sub-division of equity shares, including ADRs, in board meeting on July 27

Overview
News
Financials
Q1 2024 Results
Technicals
F&O

Analyst Rating

based on 36 analysts

HOLD

30.56%

Buy

33.33%

Hold

36.11%

Sell

Based on 36 analysts offering long term price targets for Dr Reddys Laboratories Ltd. An average target of ₹6164.31

Source: S&P Global Market Intelligence

Dr Reddys Laboratories Ltd Share analysis

Source: S&P Global Market Intelligence

Performance

  • Day's Low

    Day's High

    ₹6,793.25
    ₹6,938.9
  • 52 Week's Low

    52 Week's High

    ₹5,205.55
    ₹6,938.9
1 Month Return+ 13.38 %
3 Month Return+ 15.36 %
1 Year Return+ 27.33 %
Previous Close₹6,865.00
Open₹6,938.90
Volume6.04L
Upper Circuit-
Lower Circuit-
Market Cap₹1,14,528.59Cr

Key Statistics

P/E Ratio20.48
PEG Ratio0.32
Market Cap₹1,14,528.59 Cr
P/B Ratio4.22
EPS121.9

Mutual Fund Holdings

Funds HoldingsPrev. 6M
HDFC Flexi Cap Fund -Direct Plan - Growth OptionHDFC Flexi Cap Fund -Direct Plan - Growth Option1.43%
Parag Parikh Flexi Cap Direct GrowthParag Parikh Flexi Cap Direct Growth1.05%
Mirae Asset Large & Midcap Fund Direct Plan GrowthMirae Asset Large & Midcap Fund Direct Plan Growth1.44%
Nippon India Pharma Fund - Direct Plan - Growth PlanNippon India Pharma Fund - Direct Plan - Growth Plan6.05%
Mirae Asset ELSS Tax Saver Fund -Direct Plan-GrowthMirae Asset ELSS Tax Saver Fund -Direct Plan-Growth1.45%

Company Information

Dr Reddy's Laboratories Ltd was founded in 1984 and is based in Hyderabad, India. It is a pharmaceutical company that is listed on the Bombay Stock Exchange and National Stock Exchange of India. It has operations in over 60 countries and offers a wide range of products and services in the pharmaceuticals and healthcare sectors. The company has a strong focus on research and development and has over 6,000 employees worldwide.

Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.

Share Price: ₹6820.15 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹1,14,528.59Cr as of today
Revenue: ₹7,083.00Cr as on March 2024 (Q1 24)
Net Profit: ₹1,309.80Cr as on March 2024 (Q1 24)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
OrganisationDr Reddys Laboratories Ltd
HeadquartersHyderabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

What's happening today

  • img

    Today's Timeline - Invalid Date

    02:40 AM

    -

    Dr. Reddy's Laboratories to consider sub-division of existing equity shares, including American Depository Shares (ADS).

    06:12 AM

    -

    Board of Directors to meet on July 27 to consider the sub-division of existing equity shares.

    07:18 AM

    -

    Pharma company could soon announce a stock split; board to meet on July 27 to consider proposal.

  • img

    Today's Timeline - Invalid Date

    08:13 AM

    -

    Board of Directors set to meet on July 27 to consider a stock split proposal for Dr. Reddy's Laboratories.

    11:38 AM

    -

    Dr. Reddy's considering a stock split on July 27, subject to approval by shareholders; subsidiary acquires global consumer healthcare brands.

Key events for Dr Reddys Laboratories Ltd

  • Dr. Reddy's Laboratories Considers Stock Split Proposal - 24 Jul, 2024

    The Board of Directors of Dr. Reddy's Laboratories will meet on July 27 to consider a proposal for the sub-division of existing equity shares, including American Depository Shares. If approved, this would be the first time in recent years that the company has split its stock. The pharmaceutical company's subsidiary recently acquired global consumer healthcare brands in the Nicotine Replacement Therapy category. Despite lower-than-expected earnings in Q1 2024, CEO Erez Israeli believes current margins provide flexibility for the future.

  • Dr. Reddys Signs Licensing Agreement with Takeda for Vonoprazan Tablets - 19 Jul, 2024

    Dr. Reddys Laboratories has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to commercialise Vonoprazan tablets in India, used to treat reflux esophagitis and other acid peptic disorders.

  • Dr. Reddy's Signs Licensing Agreement with Takeda for Vonoprazan Tablets - 18 Jul, 2024

    Dr. Reddy's Laboratories has signed a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to introduce Vonoprazan tablets, a novel treatment for gastrointestinal disorders, to patients across India. The company plans to market the medication under the brand name Vono.

  • Dr. Reddys Laboratories to Pay Dividend of ₹40 per Share - 12 Jul, 2024

    Dr. Reddys Laboratories is set to pay a dividend of ₹40 per share on August 28th, with an ex-dividend date of July 17th. The company has a trailing yield of around 0.6% and a low payout ratio of just 12%. Its dividend is covered by both profits and cash flow, and the company has increased its dividend at approximately 8.3% a year on average for the past 10 years.

  • Dr. Reddys Acquires Nicotine Patch Company; Injunction Issued Against Zydus Lifesciences' Drug Sales - 11 Jul, 2024

    Dr. Reddys Laboratories has acquired a nicotine patch company, with expectations of increasing OTC revenues from 10% to 20-25% in the next few years. However, the Delhi High Court has issued an injunction against Zydus Lifesciences' sale of its breast cancer drug, Sigrima, due to a patent infringement case filed by Roche against Zydus and Dr. Reddys Laboratories.

  • Dr Reddys to Increase R&D Expenditure in FY25 - 09 Jul, 2024

    Dr Reddys Laboratories plans to increase its R&D expenditure to 8.5-9% of revenue in FY25, with a focus on biosimilars and small molecule drugs. The company's R&D expenditure increased by 18% in FY24.

  • Analysts Cautious on Dr Reddys as IPA Calls for Policy Direction - 07 Jul, 2024

    Dr Reddys Laboratories is facing a cautious stance from analysts due to various concerns, while Indian Pharmaceutical Alliance Secretary General Sudarshan Jain has called for policy direction leveraging the industry's strengths. The majority of brokerages covering the stock have given it a hold or sell rating.

  • Dr Reddys Recalls Products Due to Manufacturing Issues - 05 Jul, 2024

    Dr Reddys Laboratories is recalling drugs to treat insomnia and gout in the American market due to failed impurities/degradation specifications. The company is among those listed in the latest Enforcement Report by the US Food and Drug Administration (USFDA) for product recalls.

  • Dr Reddys Aims to Reach 1.5 Billion Patients by FY30 Through New Ventures and OTC Focus - 04 Jul, 2024

    Dr Reddys Laboratories is recalling drugs in the US market and working with the USFDA on launching biosimilar rituximab. The company aims to expand its patient base to 1.5 billion by FY30 through OTC focus and exploring new ventures like vaccines and novel molecules. Counterfeit labels of Dr Reddys products were also found, but there was no impact on the stock price.

  • Dr. Reddy's Aims for Double-Digit Growth; Focuses on Diversification - 03 Jul, 2024

    Dr. Reddy's Laboratories expects to achieve double-digit growth in revenue and operating profit this fiscal year, with plans to diversify its portfolio through injectables, complex oral solid dosage forms, OTC brands, direct-to-consumer channels, biosimilars, immune-oncology drugs, differentiated offerings, digital solutions, etc.

  • Dr. Reddys Signs Licensing Agreement with Zydus Lifesciences - 01 Jul, 2024

    Dr. Reddys Laboratories has signed a licensing agreement with Zydus Lifesciences to co-market Pertuzumab biosimilar in India under the brand names Womab and Sigrima respectively. Prabhudas Lilladher has set a buy call on Dr. Reddys with a target price of Rs 6500.

  • Dr. Reddys Acquires Nicotine Replacement Portfolio and Announces Licensing Agreement - 28 Jun, 2024

    Dr. Reddys Laboratories has announced the acquisition of UK-based Haleons nicotine replacement portfolio and a licensing agreement with Zydus Cadila to co-market Pertuzumab biosimilar in India for HER2 positive breast cancer patients.

  • Dr. Reddy's Acquires Consumer Healthcare Brands from Haleon Group - 27 Jun, 2024

    Dr. Reddy's Laboratories is set to acquire Haleon Group's portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category outside of the US for £500 million. The announcement led to a rise in Dr. Reddy's stock by 2.75%. According to Bloomberg data, out of 39 analysts tracking the company, 14 have a buy rating on the stock, as many suggest sell and 11 recommend hold.

  • Dr Reddys Acquires Global Portfolio of Consumer Healthcare Brands - 26 Jun, 2024

    Dr Reddys Laboratories is set to acquire Haleon's global portfolio of consumer healthcare brands in the nicotine replacement therapy (NRT) category outside the United States for $632.55 million. The acquisition includes the purchase of shares of Northstar Switzerland SARL, a Haleon group company. The closing of the transaction is subject to satisfactory completion of customary conditions to closing, including regulatory approvals.

Insights on Dr Reddys Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, DRREDDY stock has moved up by 3.0%

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 7.96% to 10.05% in Jun 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 26.65% of holdings in Jun 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Zydus Lifesciences Ltd has given 87.2% return, outperforming this stock by 59.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.7% return, outperforming this stock by 100.8%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 7.45K Cr → 7.31K Cr (in ₹), with an average decrease of 1.9% per quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 10.38% to 10.19% in Jun 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 1.48K Cr → 1.30K Cr (in ₹), with an average decrease of 6.0% per quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 29.14% to 27.68% in Jun 2024 quarter

News

Dr Reddy's to Consider Stock Split on 27 July, Shares Trading Flat

Shares of Dr Reddy's Laboratories Ltd. are trading flat after touching a day's high of Rs 6,938.90 on 24 July, after the company announced a consideration for a... Read more

24 Jul, 2024 11:38 AM

Dr. Reddy's to consider stock split on July 27, shares close lower

In the exchange filing, Dr Reddy's Labs said that the board will determine the alteration in the company's share capital by sub-division of shares, subject to t... Read more

24 Jul, 2024 03:53 PM

Dr Reddys Laboratories Share Price Today - Dr Reddys Laboratories Stock Price Live NSE/BSE

Dr Reddys Laboratories Share Price Today - 24 Jul 2024: Find Dr Reddys Laboratories Stock Price Live updates on Mint. Check out Dr Reddys Laboratories share pri... Read more

24 Jul, 2024 05:30 PM
View More

Company Financials

Value in ₹ crore
Q'1 24Q/Q Change
Revenue
₹7,083.00Cr
↓1.83%
Net Income
₹1,309.80Cr
↓5.15%
Net Profit Margin
18.49%
↓3.40%
2024Y/Y Change
Revenue
₹28,011.10Cr
↑13.54%
Net Income
₹5,577.90Cr
↑23.75%
Net Profit Margin
19.91%
↑8.98%
Value in ₹ crore
2024Y/Y Change
Total Assets
₹30,359.30Cr
↑19.64%
Total Liabilities
₹6,118.50Cr
↑24.85%
Value in ₹ crore
2024Y/Y Change
Operating Cash Flow
₹3,449.70Cr
↓31.73%

Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
26.65%
-0.01
Foreign Institutions
27.68%
-5.01
Mutual Funds
10.05%
26.33
Retail Investors
10.19%
-1.83
Others
25.43%
-1.71

Key Indicators

Dr Reddys Laboratories Ltd Valuation

Dr Reddys Laboratories Ltd in the last 5 years

  • Overview

  • Trends

Lowest (15.84x)

October 7, 2019

Today (20.48x)

July 23, 2024

Industry (56.07x)

July 23, 2024

Highest (53.88x)

December 18, 2020

LowHigh

Earnings and Dividends

  • Dr Reddys Laboratories Ltd Earnings Results

    Dr Reddys Laboratories Ltd’s net profit jumped 36.42% since last year same period to ₹1,309.80Cr in the Q4 2023-2024. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated -5.15% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Dr Reddys Laboratories Ltd Dividends May,2024

    In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 1.17%.

    Read More about Dividends

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Dr Reddys Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Dr Reddys Laboratories Ltd shares.

Dr Reddys Laboratories Ltd (DRREDDY) share price today is ₹6820.15

Dr Reddys Laboratories Ltd is listed on NSE

Dr Reddys Laboratories Ltd is listed on BSE

  • Today’s highest price of Dr Reddys Laboratories Ltd is ₹6938.9.
  • Today’s lowest price of Dr Reddys Laboratories Ltd is ₹6793.25.

PE Ratio of Dr Reddys Laboratories Ltd is 20.48

PE ratio = Dr Reddys Laboratories Ltd Market price per share / Dr Reddys Laboratories Ltd Earnings per share

Today’s traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 6.04L.

Today’s market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹114528.59Cr.

Dr Reddys Laboratories Ltd(DRREDDYPrice
52 Week High
₹6938.9
52 Week Low
₹5205.55

Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹6820.15. It is down -1.71% from its 52 Week High price of ₹6938.9

Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹6820.15. It is up 31.02% from its 52 Week Low price of ₹5205.55

Dr Reddys Laboratories Ltd(DRREDDYReturns
1 Day Returns
-44.85%
1 Month Returns
13.38%
3 Month Returns
15.36%
1 Year Returns
27.33%